RES inhibits the interleukin‐6 (IL‐6)‐induced transcriptional activity of STAT3 in human prostate cancer LNCaP‐FGC cells18 and STAT3 axis in primary glioblastoma tumor‐initiating cells.19 Here, STAT3 is linked to prostate carcinoma.